News

September 22, 2023

Rhythm Pharmaceuticals Presents New Data at ESPE 2023

September 19, 2023

Rhythm Pharmaceuticals Receives Orphan Drug Designation from European Medicines Agency for Setmelanotide for Treatment of Acquired Hypothalamic Obesity

September 8, 2023

Rhythm Pharmaceuticals Announces New Employment Inducement Grants

September 8, 2023

Rhythm Pharmaceuticals Announces Update to September Conference Participation

September 6, 2023

Rhythm Pharmaceuticals Announces New ICD-10 Diagnosis Code Established for Bardet-Biedl Syndrome

August 28, 2023

Rhythm Pharmaceuticals to Present at Investor Conferences in September

August 7, 2023

Rhythm Pharmaceuticals Announces Pre-Marketing Early Access Authorization for Setmelanotide for Use in Patients with Hypothalamic Obesity in France

August 4, 2023

Rhythm Pharmaceuticals Announces New Employment Inducement Grants

August 1, 2023

Rhythm Pharmaceuticals Reports Second Quarter 2023 Financial Results and Business Update

July 19, 2023

Rhythm Pharmaceuticals Announces Two Publications Detailing Burden of Hyperphagia and Obesity on Patients and Caregivers Living with Bardet-Biedl Syndrome

July 17, 2023

Rhythm Pharmaceuticals to Report Second Quarter 2023 Financial Results on Tuesday, August 1, 2023

July 13, 2023

Rhythm Pharmaceuticals Announces New Employment Inducement Grants

June 17, 2023

Rhythm Pharmaceuticals Presents Data Demonstrating BMI Reduction in Patients with Hypothalamic Obesity Treated with Setmelanotide over Six Months at ENDO 2023

June 7, 2023

Rhythm Pharmaceuticals to Present at Goldman Sachs 44th Annual Global Healthcare Conference

June 6, 2023

Rhythm Pharmaceuticals Announces New Employment Inducement Grants

May 22, 2023

Rhythm Pharmaceuticals and Genpharm Announce Collaboration to Provide IMCIVREE® (setmelanotide) to Patients in Gulf Cooperation Council Countries

May 8, 2023

Rhythm Pharmaceuticals Announces Health Canada Approval of IMCIVREE® Setmelanotide Injection for Weight Management in Bardet-Biedl Syndrome or Genetically-confirmed Biallelic POMC, PCSK1, or LEPR Deficiency

May 5, 2023

Rhythm Pharmaceuticals Announces New Employment Inducement Grants

May 2, 2023

Rhythm Pharmaceuticals Reports First Quarter 2023 Financial Results and Business Update

April 24, 2023

Rhythm Pharmaceuticals Announces Commercial Launch of IMCIVREE® (setmelanotide) in Germany for the Treatment of Obesity and Control of Hunger in Bardet-Biedl Syndrome

April 18, 2023

Rhythm Pharmaceuticals to Report First Quarter 2023 Financial Results on Tuesday, May 2, 2023

April 10, 2023

Rhythm Pharmaceuticals to Present at 22nd Annual Needham Virtual Healthcare Conference

April 6, 2023

Rhythm Pharmaceuticals Announces New Employment Inducement Grants

March 27, 2023

Rhythm Pharmaceuticals Announces Publication of Bardet-Biedl Syndrome Patient and Caregiver Perspectives of Hunger and Quality of Life with Setmelanotide

March 6, 2023

Rhythm Pharmaceuticals Announces New Employment Inducement Grants

March 1, 2023

Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results

February 27, 2023

Rhythm Pharmaceuticals Announces Acquisition of Xinvento B.V. and Portfolio of Investigational Therapeutics

February 21, 2023

Rhythm Pharmaceuticals to Report Fourth Quarter and Full Year 2022 Financial Results on Wednesday, March 1, 2023

February 8, 2023

Rhythm Pharmaceuticals Announces New Employment Inducement Grants

January 23, 2023

Rhythm Pharmaceuticals Announces Publication of Analysis of Quality of Life Improvements from Phase 3 Clinical Trial in Bardet-Biedl Syndrome

January 5, 2023

Rhythm Pharmaceuticals Announces New Employment Inducement Grants